Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: A randomized, prospective trial

Jung U. Shin, Jihun Park, Sang Ho Oh, Ju Hee Lee

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders. Objective To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma. Materials and methods Forty-eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale. Results Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group. Conclusions Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.

Original languageEnglish
Pages (from-to)435-442
Number of pages8
JournalDermatologic Surgery
Volume39
Issue number3 PART 1
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Tranexamic Acid
Melanosis
Solid-State Lasers
Lasers
Therapeutics
Laser Therapy
Safety

All Science Journal Classification (ASJC) codes

  • Surgery
  • Dermatology

Cite this

@article{ed098f28a9d748a9a19b100dd322ae5a,
title = "Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: A randomized, prospective trial",
abstract = "Background Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders. Objective To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma. Materials and methods Forty-eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale. Results Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group. Conclusions Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.",
author = "Shin, {Jung U.} and Jihun Park and Oh, {Sang Ho} and Lee, {Ju Hee}",
year = "2013",
month = "3",
day = "1",
doi = "10.1111/dsu.12060",
language = "English",
volume = "39",
pages = "435--442",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "3 PART 1",

}

TY - JOUR

T1 - Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans

T2 - A randomized, prospective trial

AU - Shin, Jung U.

AU - Park, Jihun

AU - Oh, Sang Ho

AU - Lee, Ju Hee

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Background Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders. Objective To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma. Materials and methods Forty-eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale. Results Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group. Conclusions Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.

AB - Background Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders. Objective To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma. Materials and methods Forty-eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale. Results Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group. Conclusions Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.

UR - http://www.scopus.com/inward/record.url?scp=84874739095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874739095&partnerID=8YFLogxK

U2 - 10.1111/dsu.12060

DO - 10.1111/dsu.12060

M3 - Article

C2 - 23278870

AN - SCOPUS:84874739095

VL - 39

SP - 435

EP - 442

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 3 PART 1

ER -